About
EyeArt screens diabetic retinopathy from fundus images, cleared for autonomous (no physician review) use. First AI cleared by the FDA for multiple retinal cameras (2023). Sold as a camera-agnostic screening product for primary care, endocrinology and pharmacy settings.
HQ: Woodland Hills, California, USA
Funding
$26M Series A (Oct 2022, AXA IM Alts-led); >$43M total at that time
Filed a new ~$5.65M exempt offering in July 2026.